lcabie

Pre-retinal delivery of recombinant adeno-associated virus vector significantly improves retinal transduction efficiency

Intravitreal injection is essentially the most extensively used injection method for ocular gene supply. Nevertheless, vector diffusion is attenuated by bodily boundaries and neutralizing antibodies within the vitreous. The 13-lined floor squirrel (13-LGS), as in people, has a bigger relative vitreous physique quantity than the extra widespread rodent fashions corresponding to rats and mice, which might additional cut back transduction effectivity with the intravitreal injection route. We report right here a “pre-retinal” injection strategy that results in detachment of the posterior hyaloid membrane and delivers vector into the area between vitreous and interior retina.
Vectors carrying a ubiquitously expressing mCherry reporter have been injected into the deep vitreous or pre-retinal area in grownup wild-type 13-LGSs. Then, adeno-associated virus (AAV)-mediated mCherry expression was evaluated with non-invasive imaging, immunofluorescence, and stream cytometry. In comparison with deep vitreous supply, pre-retinal administration achieved pan-retinal gene expression with a decrease vector dose quantity and considerably elevated the variety of transduced cone photoreceptors.
These outcomes counsel that pre-retinal injection is a promising software within the growth of gene remedy methods in animal fashions and is a possible strategy to be used in human analysis, notably in youthful people with an intact posterior hyaloid membrane and secure vitreous.

A delicate and reproducible cell-based assay through secNanoLuc to detect neutralizing antibody towards adeno-associated virus vector capsid

Most gene remedy medical trials that systemically administered adeno-associated virus (AAV) vector enrolled solely sufferers with out anti-AAV-neutralizing antibodies. Nevertheless, laboratory exams to measure neutralizing antibodies various amongst medical trials and haven’t been standardized. On this research, we tried to enhance the sensitivity and reproducibility of a cell-based assay to detect neutralizing antibodies and to find out the detection threshold to foretell remedy efficacy.
Utility of the secreted sort of NanoLuc and AAV receptor-expressing cells diminished the multiplicity of an infection (MOI) for AAV transduction and improved the sensitivity to detect neutralizing antibodies with a low coefficient of variation, whereas the detection threshold couldn’t be improved by the discount of MOI to <100. After human immunoglobulin administration into mice at numerous doses, remedy with high-dose AAV8 vector enabled evasion of the inhibitory impact of neutralizing antibodies.
Conversely, gene transduction was barely influenced within the mice handled with low-dose AAV8 vector, even when neutralizing antibodies have been decided to be unfavorable within the assay. In conclusion, we developed a dependable and delicate cell-based assay to measure neutralizing antibodies towards AAV and located that the suitable MOI to detect marginal neutralizing antibodies was 100. Different components, together with noninhibitory antibodies, marginally affect in vivo transduction at low vector doses.
lcabie
lcabie

Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine

Goal: The aim of this research was to report an uncommon case of bilateral immune-mediated corneal melting and necrosis after ChAdOx1 nCoV-19 (Covishield) vaccination.
Strategies: This can be a case report and literature assessment.
Outcomes: A 48-year-old man introduced to the ophthalmic emergency division with progressive bilateral corneal melting 5 weeks after receiving the primary dose of ChAdOx1 nCoV-19 (Covishield) vaccine. Systemic complaints of fever, diarrhea, and vomiting have been famous within the first 2 weeks, which subsided earlier than the onset of ocular signs at day 21 of vaccine administration.
The affected person may solely understand mild bilaterally and demonstrated options of bilateral keratolysis with choroidal detachment on ultrasonography. The microbiological scraping specimen didn’t reveal development of any microorganism. Tectonic penetrating keratoplasty was carried out, and the host corneal tissue was despatched for histopathology, bacterial tradition, fungal tradition, polymerase chain response for herpes simplex virus, varicella zoster virus, cytomegalovirus, adenovirus, and SARS-CoV-2. Microbial tradition was sterile, and viral polymerase chain response stories have been unfavorable.
Histopathological examination revealed dense inflammatory cell infiltration. Detailed systemic workup revealed no underlying systemic or autoimmune pathology.
Conclusions: Immune-mediated keratolysis after ChAdOx1 nCoV-19 (Covishield) vaccination is a uncommon entity, and we consider that that is the primary report of a temporal affiliation between a severe ocular hostile occasion after a single dose of any SARS-CoV-19 vaccine. It might be included as a potential hostile occasion related to this vaccine.

Manufacturing of therapeutic iduronate-2-sulfatase enzyme with a novel single-stranded RNA virus vector

The Sendai virus vector has obtained plenty of consideration as a result of its broad tropism for mammalian cells. Because of efforts for genetic research primarily based on a mutant virus, we will now categorical greater than 10 genes of as much as 13.5 kilo nucleotides in a single vector with excessive protein expression effectivity. To show this profit, we examined the efficacy of the novel ribonucleic acid (RNA) virus vector harboring the human iduronate-2-sulfatase (IDS) gene with 1,653 base pairs, a causative gene for mucopolysaccharidosis sort II, also called a dysfunction of lysosomal storage issues.

As anticipated, this novel RNA vector with the human IDS gene exhibited its marked expression as decided by the expression of enhanced inexperienced fluorescent protein and IDS enzyme exercise. Whereas these cells exhibited a standard development fee, the BHK-21 transformant cells stably expressing the human IDS gene persistently generated an lively human IDS enzyme extracellularly. The human IDS protein produced didn’t be included into the lysosome when cells have been pretreated with mannose-6-phosphate, demonstrating that this human IDS enzyme has potential for therapeutic use by cross-correction. These outcomes counsel that our novel RNA vector could also be relevant for additional medical settings.

MVAΔ008 viral vector encoding the mannequin protein OVA induces improved immune response towards the heterologous antigen and equal ranges of safety in a mice tumor mannequin than the standard MVA

 

Modified vaccinia Ankara virus (MVA) is extensively used as a vaccine vector. Now we have beforehand noticed that MVAΔ008, an MVA missing the gene that codes for interleukin-18 binding protein, considerably will increase CD8+ and CD4+ T-cell responses to vaccinia virus (VACV) epitopes and recombinant HIV antigens. Nevertheless, the efficacy of this vector towards pathogens or tumor cells stays unclear.
Thus, the intention of this research was to judge the mobile immune response and the safety induced by recombinant MVAs encoding the mannequin antigen ovalbumin (OVA). We used the MO5 melanoma tumor mannequin (OVA-expressing tumor) as an strategy for evaluating the vector-induced efficacy. Our outcomes present that MVAΔ008-OVA (optimized vector) induced greater in vivo particular cytotoxicity and ex vivo T-cell IFN-γ responses towards OVA than the standard MVA vector.
Importantly, the recombinant vectors have been able to controlling MO5 tumor development. Certainly, the administration of MVAΔ008-OVA or MVA-OVA in prophylactic and therapeutic schemes offered whole safety and longer survival of mice, respectively. Total, our outcomes reveal the improved immunogenicity and the protecting capability of MVAΔ008 towards a heterologous mannequin antigen. These findings counsel that MVAΔ008 constitutes a superb candidate for vaccine growth towards pathogens or most cancers remedy.

anti-Galectin 1

YF-PA12945 100 ug
EUR 403
Description: Rabbit polyclonal to Galectin 1

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 349

Anti-Galectin 1 Antibody

A00470-2 100ug/vial
EUR 294

Anti-Galectin-1 antibody

STJ98716 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-1.

Anti-Galectin-1 antibody

STJ93201 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-1.

anti- Galectin-1 antibody

FNab03314 100µg
EUR 505.25
Description: Antibody raised against Galectin-1

anti- Galectin-1 antibody

FNab03315 100µg
EUR 548.75
Description: Antibody raised against Galectin-1

Anti-Galectin-1 antibody

PAab03314 100 ug
EUR 355

Anti-Galectin 1 (1A8)

YF-MA13984 100 ug
EUR 363
Description: Mouse monoclonal to Galectin 1

Anti-Galectin 1/LGALS1 Antibody

PA1422 100ug/vial
EUR 334

Anti-Galectin 1/LGALS1 Antibody

PB9240 100ug/vial
EUR 334

Anti-Galectin 1/Lgals1 Antibody

A00470 100ug/vial
EUR 334

Anti-Galectin 1 Biotinylated Antibody

A00470-Biotin 50ug/vial
EUR 294

Anti-galectin-1 (mouse) antibody

STJ72519 100 µg
EUR 359

anti-Galectin 1 (1E8-1B2)

LF-MA10174 100 ug
EUR 363
Description: Mouse monoclonal to Galectin 1

Anti-Galectin-13 (GAL13) / Placental Protein 13 (PP13) Monoclonal Antibody

M08143-1 100ug/vial
EUR 397
Description: Mouse Monoclonal Galectin-13 (GAL13) / Placental Protein 13 (PP13) Antibody. Validated in IHC and tested in Human.

anti-Galectin 3

YF-PA12946 50 ug
EUR 363
Description: Mouse polyclonal to Galectin 3

anti-Galectin 3

YF-PA12947 100 ul
EUR 403
Description: Rabbit polyclonal to Galectin 3

anti-Galectin 3

YF-PA12948 100 ug
EUR 403
Description: Rabbit polyclonal to Galectin 3

anti-Galectin 8

YF-PA12951 50 ul
EUR 363
Description: Mouse polyclonal to Galectin 8

anti-Galectin 3

YF-PA24079 50 ul
EUR 334
Description: Mouse polyclonal to Galectin 3

anti-galectin 9

YF-PA24081 50 ul
EUR 334
Description: Mouse polyclonal to galectin 9

anti-Galectin 13

YF-PA18585 50 ug
EUR 363
Description: Mouse polyclonal to Galectin 13

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

Anti-human Galectin-3 antibody

STJ15100163 250 µg
EUR 336
Description: This monoclonal antibody is for studies of antigen expression in cells and tissue sections using immunocytochemistry and immunoprecipitation

LGALS7 Human, Galectin-7 Human Recombinant Protein, His Tag

PROTP47929-1 Regular: 20ug
EUR 317
Description: Galectin-7 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 156 amino acids (1-136 a.a.) and having a molecular mass of 17.2kDa. ;The Galectin-7 is purified by proprietary chromatographic techniques.

LGALS3 Human, Galectin-3 Human Recombinant Protein, His Tag

PROTP17931-1 Regular: 25ug
EUR 317
Description: LGALS3 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 270 amino acids (1-250 a.a.) and having a molecular mass of 28.3 kDa._x000D_ The LGALS3 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. _x000D_

LGALS8 Human, Galectin-8 Human Recombinant Protein, His Tag

PROTO00214-1 Regular: 10ug
EUR 317
Description: LGALS8 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 337 amino acids (1-317 a.a.) and having a molecular mass of 37.9 kDa. The LGALS8 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques.

Human Galectin-3 (Gal-3) AssayMax ELISA Kit

EG3311-1 96 Well Plate
EUR 477

Human Galectin-4 (Gal-4) AssayMax ELISA Kit

EG3312-1 96 Well Plate
EUR 477

Human Galectin-1 (LGALS1)

1-CSB-EP012882HU
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli

Human Galectin-1 (LGALS1)

1-CSB-EP012882HUb1
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli

Human Galectin 1 Protein

20-abx066725
  • EUR 620.00
  • EUR 272.00
  • EUR 1859.00
  • EUR 732.00
  • EUR 453.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Recombinant Human Galectin-1

7-00427 10µg Ask for price

Recombinant Human Galectin-1

7-00428 50µg Ask for price

Recombinant Human Galectin-1

7-00429 1mg Ask for price

Galectin-1, human recombinant

4648-10
EUR 142

Galectin-1, human recombinant

4648-1000
EUR 1648

Galectin-1, human recombinant

4648-50
EUR 262

Anti-Galectin-3 antibody

STJ16100369 1 mL
EUR 1047

Anti-Galectin-3 antibody

STJ16100782 100 µg
EUR 720

Anti-Galectin-3 antibody

STJ180106 0.1 ml
EUR 212

Anti-Galectin 3 antibody

STJ190057 200 µl
EUR 197
Description: Unconjugated Mouse monoclonal to Galectin 3 (AS1A24)

Anti-Galectin-9 Antibody

A03415 100ul
EUR 397
Description: Rabbit Polyclonal Antibody for Galectin-9 Antibody (LGALS9) detection.tested for WB in Human, Mouse, Rat.

Anti-Galectin-3 antibody

STJ96945 200 µl
EUR 197
Description: Galectin-3 is a protein encoded by the LGALS3 gene which is approximately 26,1 kDa. Galectin-3 is localised to the cytoplasm and nucleus. It is involved in NF-kappaB signalling, advanced glycosylation end product receptor signalling and cell adhesion. It is a galactose-specific lectin which binds IgE and may mediate the stimulation by CSPG4 of endothelial cells migration along with the alpha-3, beta-1 integrin. It is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. Galectin-3 is expressed mainly in the colonic epithelium and is also abundantly expressed in activated macrophages. Mutations in the LGALS3 gene may result in follicular adenoma and thyroid cancer. STJ96945 was developed from clone 6G2 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous galectin-3 proteins.

Anti-Galectin-3 antibody

STJ97549 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (6B8).

Anti-Galectin-3 antibody

STJ97550 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (8D7).

Anti-Galectin-3 antibody

STJ97551 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (5D9).

Anti-Galectin-3 antibody

STJ97601 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (2F9).

Anti-Galectin-3 antibody

STJ97604 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (16E6).

Anti-Galectin-3 antibody

STJ97605 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (1H4).

Anti-Galectin-3 antibody

STJ97715 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3.

Anti-Galectin-2 antibody

STJ93202 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-2.

Anti-Galectin-4 antibody

STJ93203 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-4.

Anti-Galectin-7 antibody

STJ93204 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-7.

Anti-Galectin-8 antibody

STJ93205 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-8.

Anti-Galectin-9 antibody

STJ93206 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-9.

Anti-Galectin 3 antibody

STJ73098 100 µg
EUR 359

anti- Galectin 2 antibody

FNab03310 100µg
EUR 585
Description: Antibody raised against Galectin 2

anti- Galectin 4 antibody

FNab03311 100µg
EUR 505.25
Description: Antibody raised against Galectin 4

anti- Galectin 8 antibody

FNab03312 100µg
EUR 505.25
Description: Antibody raised against Galectin 8

anti- Galectin 9 antibody

FNab03313 100µg
EUR 505.25
Description: Antibody raised against Galectin 9

anti- Galectin-3 antibody

FNab03316 100µg
EUR 505.25
Description: Antibody raised against Galectin-3

anti- Galectin-3 antibody

FNab03317 100µg
EUR 548.75
Description: Antibody raised against Galectin-3

anti- Galectin-7 antibody

FNab03318 100µg
EUR 505.25
Description: Antibody raised against Galectin-7

anti-Galectin-3 (6G2)

LF-MA20336 100 ug
EUR 354
Description: Mouse monoclonal to Galectin-3

Anti-Galectin 2 antibody

PAab03310 100 ug
EUR 412

Anti-Galectin 4 antibody

PAab03311 100 ug
EUR 355

Anti-Galectin 8 antibody

PAab03312 100 ug
EUR 355

Anti-Galectin 9 antibody

PAab03313 100 ug
EUR 355

Anti-Galectin-3 antibody

PAab03316 100 ug
EUR 355

Anti-Galectin-7 antibody

PAab03318 100 ug
EUR 355

Anti-Galectin 8 (3E5)

YF-MA13986 100 ug
EUR 363
Description: Mouse monoclonal to Galectin 8

Anti-galectin-1 (mouse) (aa100-112) antibody

STJ72520 100 µg
EUR 359

Anti Human Galectin-3 Polyclonal Antibody

KH040
EUR 649
Description: The Anti Human Galectin-3 Polyclonal Antibody is available in Europe and for worldwide shipping via Gentaur.

Anti-Galectin-1 / Human Placental Lactogen (hPL) Monoclonal Antibody

M00470 100ug/vial
EUR 397
Description: Mouse Monoclonal Galectin-1 / Human Placental Lactogen (hPL) Antibody. Validated in IHC and tested in Human.

Galectin-1 (LGAS1)

PR27143 50 ug
EUR 318

Galectin 1 Antibody

49673-100ul 100ul
EUR 333

Galectin 1 Antibody

49673-50ul 50ul
EUR 239

Galectin-1 Protein

20-abx261634
  • EUR 3418.00
  • EUR 328.00
  • EUR 230.00
  • 1 mg
  • 20 ug
  • 5 ug

Galectin-1 Protein

20-abx263505
  • EUR 230.00
  • EUR 1790.00
  • EUR 328.00
  • 10 ug
  • 1 mg
  • 50 ug

rHu Galectin-1

AK8281-0010 10µg Ask for price

rHu Galectin-1

AK8281-0050 50µg Ask for price

rHu Galectin-1

AK8281-0100 100µg Ask for price

rHu Galectin-1

AK8281-1000 1mg Ask for price

Galectin-1 Antibody

3596-100
EUR 316

Galectin-1 Antibody

3596-30T
EUR 146

Galectin 1 protein

30R-1385 100 ug
EUR 224
Description: Purified recombinant Human Galectin 1 protein